NEW YORK and WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public
Began trading on Nasdaq under the ticker symbol DNTH following the successful completion of our merger with Magenta Therapeutics Completed concurrent $72 million financing with a syndicate of leading life-science investors Announced positive top-line Phase 1 data for lead clinical program, DNTH103,
NEW YORK and WALTHAM, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the Company’s senior management team will participate in the following
Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially differentiated safety profile Results support DNTH103’s best-in-class potential to be the first subcutaneous, self-administered injection dosed as
The combined company will operate as “Dianthus Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “DNTH” effective Tuesday, September 12, 2023 CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) today announced
Experienced life sciences executive brings more than a decade of public company expertise in legal, corporate governance and compliance New York City and Waltham, Mass., June 20, 2023 – Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million
Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H’23 DNTH103 is a next-generation monoclonal antibody that selectively targets only the active form of the C1s protein in the classical complement
Lead program DNTH103 to be accelerated to the clinic this year as a highly differentiated and potent monoclonal antibody designed to selectively target the active form of complement C1s Led by biotech veterans Marino Garcia as Chief Executive Officer and Lonnie Moulder as Chairman of the Board
